Table 3.
Surgical uterine evacuation by trial characteristics in groups treated with 800 mcg misoprostol vaginally
Trial groups N=31 |
Evaluable women N=10010 | Women who had surgical uterine evacuation N=1895 |
ORa | ||||
---|---|---|---|---|---|---|---|
N | % | OR | 95% CI | ||||
3–100 | 15 | 823 | 193 | 23% | 1 | ||
101–500 | 11 | 2098 | 209 | 10% | 0.36 | 0.21 | 0.61 |
501–720 | 3 | 1745 | 242 | 14% | 0.53 | 0.30 | 0.93 |
2805, 3225 | 2 | 5344 | 1251 | 23% | 1.00 | 0.62 | 1.60 |
Lost to follow-up in group | |||||||
0 | 22 | 2991 | 390 | 13% | 1 | ||
>0 to 10% | 7 | 1675 | 254 | 15% | 1.19 | 0.81 | 1.75 |
>10% | 2 | 5344 | 1251 | 23% | 2.04 | 1.56 | 2.66 |
Publication date | |||||||
1994–1999 | 8 | 1342 | 164 | 12% | 1 | ||
2000–2004 | 12 | 4704 | 859 | 18% | 1.60 | 0.91 | 2.82 |
2005-present | 11 | 3964 | 872 | 22% | 2.03 | 1.39 | 2.96 |
Study design | |||||||
randomized | 12 | 1602 | 311 | 19% | 1 | ||
prospective cohort or case series | 15 | 2603 | 284 | 11% | 0.51 | 0.35 | 0.74 |
retrospective cohort or case series | 4 | 5805 | 1300 | 22% | 1.20 | 0.82 | 1.74 |
Region | |||||||
North America | 6 | 841 | 95 | 11% | 1 | ||
Asia | 12 | 668 | 157 | 24% | 1.97 | 1.25 | 3.11 |
Latin or South America | 8 | 7102 | 1426 | 20% | 2.41 | 1.16 | 5.03 |
other or multiple | 5 | 1399 | 217 | 16% | 1.44 | 0.95 | 2.20 |
Planned maximum gestational age | |||||||
42–56 days | 14 | 3905 | 743 | 19% | 1 | ||
57–63 days | 11 | 2742 | 380 | 14% | 0.68 | 0.43 | 1.09 |
≥63 days | 6 | 3363 | 772 | 23% | 1.27 | 0.85 | 1.89 |
Misoprostol moistened before vaginal administration | |||||||
no or not stated | 11 | 6093 | 1419 | 23% | 1 | ||
yes | 20 | 3917 | 476 | 12% | 0.46 | 0.35 | 0.60 |
Total number of allowed doses | |||||||
1 | 4 | 305 | 78 | 26% | 1 | ||
2 | 8 | 2862 | 656 | 23% | 0.87 | 0.47 | 1.60 |
3 | 16 | 6221 | 1106 | 18% | 0.63 | 0.30 | 1.31 |
4+ | 3 | 622 | 55 | 9% | 0.28 | 0.14 | 0.57 |
Maximum duration of dosing if all allowed contingent doses were taken | |||||||
0 (only 1 dose allowed) | 4 | 305 | 78 | 26% | 1 | ||
1–24h | 9 | 3759 | 817 | 22% | 0.81 | 0.42 | 1.54 |
25–48h | 9 | 5138 | 910 | 18% | 0.63 | 0.29 | 1.37 |
>48 h | 9 | 808 | 90 | 11% | 0.36 | 0.16 | 0.82 |
Protocol permitted patient to take misoprostol at home | |||||||
all or some | 13 | 8558 | 1663 | 19% | 1 | ||
none | 18 | 1452 | 232 | 16% | 0.79 | 0.49 | 1.26 |
Evaluated by ultrasound prior to decision to perform surgery | |||||||
all patients | 29 | 8985 | 1729 | 19% | 1 | ||
some or no patients | 2 | 1025 | 166 | 16% | 0.81 | 0.62 | 1.06 |
Earliest timing of decision re. surgery | |||||||
≤72h | 10 | 4403 | 893 | 20% | 1 | ||
73h-7d | 8 | 1087 | 133 | 12% | 0.55 | 0.31 | 0.96 |
>7d | 13 | 4520 | 869 | 19% | 0.94 | 0.59 | 1.49 |
Confidence intervals are adjusted for clustering by paper.